Psychiatric drug use among patients of a community mental health service: Patterns and implications

Disease Management and Health Outcomes

Volumn 14, Issue 6, 2006, Pages 369-376

  Gisev, Natasa ^a   Bell, J Simon ^a,b   McLachlan, Andrew J ^a,c   Chetty, Manoranjenni ^a   Chen, Timothy F ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF HELSINKI   (Finland)

^c ANZAC Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZUCLOPENTHIXOL;

ALTERNATIVE MEDICINE; ARTICLE; BIPOLAR DISORDER; DRUG MISUSE; DRUG MONITORING; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; PRESCRIPTION; PSYCHOSIS; PUBLIC HEALTH; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEMI STRUCTURED INTERVIEW;

EID: 33846275793     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200614060-00006     Document Type: Article

References (73)

1. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997; 6: 10-8
2. Gareri P, De Fazio P, Stilo M, et al. Conventional and atypical antipsychotics in the elderly: a review. Clin Drug Invest 2003; 23: 287-322
3. Lambert TJR, Chapman L, Bell S, et al. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-8
4. Castle DJ, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients' perspective. Aust N Z J Psychiatry 2002; 36: 633-41
5. Happell B, Manias E, Roper C. Wanting to be heard: mental health consumers' experiences of information about medication. Int J Ment Health Nurs 2004; 13: 242-8
6. Keks NA, Alston K, Hope J, et al. Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 1999; 33: 896-901
7. Snowdon J, Day S, Baker W. Why and how antipsychotic drugs are used in 40 Sydney nursing homes. Int J Geriatr Psychiatry 2005; 20: 1146-52
8. Oborne CA, Hooper R, Chi Li K, et al. An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing 2002; 31: 435-9
9. Owen RR, Thrush CR, Kirchner JE, et al. Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose. Int J Qual Health Care 2000; 12: 475-82
10. Leslie DL, Rosenheck RA. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 2001; 39: 923-33
11. Harrington M, Lelliott P, Paton C, et al. The results of a multi-centre audit of prescribing of antipsychotic drugs for inpatients in the UK. Psychiatr Bull 2002; 26: 414-8
12. Paton C, Lelliott P. The use of prescribing indicators to measure the quality of care in psychiatric inpatients. Qual Saf Health Care 2004; 13: 40-5
13. Meagher D, Moran M. Sub-optimal prescribing in an adult community mental health service: prevalence and determinants. Psychiatr Bull 2003; 27: 266-70
14. Callaly T, Trauer T. Patterns of use of antipsychotic medication in a regional community mental health service. Australas Psychiatry 2000; 8: 220-4
15. Viola R, Csukonyi K, Doro P, et al. Reasons for polypharmacy among psychiatric patients. Pharm World Sci 2004; 26: 143-7
16. How to investigate drug use in health facilities. Geneva: World Health Organization, 1993
17. Schmidt IK, Fastbom J. Quality of drug use in Swedish nursing homes: a follow up study. Clin Drug Invest 2000; 20: 433-46
18. van Dijk KN, Pont LG, de Vries CS, et al. Prescribing indicators for evaluating drug use in nursing homes. Ann Pharmacother 2003; 37: 1136-41
19. Oborne CA, Hooper R, Swift CG, et al. Explicit, evidence-based criteria to assess the quality of prescribing to elderly nursing home residents. Age Ageing 2003; 32: 102-8
20. Oborne CA, Batty GM, Maskrey V, et al. Development of prescribing indicators for elderly medical inpatients. Br J Clin Pharmacol 1997; 43: 91-7
21. Elliott RA, Woodward MC, Oborne CA. Indicators of prescribing quality for elderly hospital inpatients. Aust J Hosp Pharm 2001; 31: 19-25
22. Harvey CA, Fielding JM. The configuration of mental health services to facilitate care for people with schizophrenia. Med J Aust 2003; 178: S49-52
23. Alderman CP, Kiepfer B. Complementary medicine use by psychiatry patients of an Australian hospital. Ann Pharmacother 2003; 37: 1779-84
24. Bell JS, Whitehead P, Aslani P, et al. Drug related problems in the community setting: pharmacists' findings and recommendations for people with mental illnesses. Clin Drug Invest 2006; 26: 415-25
25. MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 2006; 184: 27-31
26. Carney SL. Medication accuracy and general practitioner referral letters. Intern Med J 2006; 36: 132-4
27. Cockayne NL, Duguid M, Shenfield GM. Health professionals rarely record history of complementary and alternative medicines. Br J Clin Pharmacol 2004; 59: 254-8
28. Bell JS, Whitehead P, Aslani P, et al. Design and implementation of an educational partnership between community pharmacists and consumer educators in mental health care. Am J Pharm Educ 2006; 70: 28
29. Therapeutic guidelines: psychotropic version 5. Melbourne (Australia): Therapeutic Guidelines Limited, 2003
30. Australian medicines handbook. Adelaide (Australia): Australian Medicines Handbook Pty Ltd, 2006
31. Thomson MicroMedex. Drug-Reax® system [online]. Available from URL: http://www.micromedex.com/products/drugreax/ [Accessed 2006 Nov 18]
32. Beaubrun G, Gray GE. A review of herbal medicines use psychiatric disorders. Psychiatr Serv 2000; 51: 1130-4
33. Rathbone J, Zhang L, Xia J, et al. Chinese herbal medicine for schizophrenia. Cochrane Database Syst Rev 2005; (4): CD003444
34. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2006; (3): CD001257
35. Coxeter PD, McLachlan AJ, Duke CC, et al. Herb-drug interactions: an evidence based approach. Curr Med Chem 2004; 11: 1513-25
36. Henderson L, Yue QY, Bergquist C, et al. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349-56
37. Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57: 592-9
38. Davis JM, Chen N. Dose response of dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24: 192-208
39. Taylor D, Paton C, Kerwin R. The Maudsley 2005-2006 prescribing guidelines. London: Taylor and Francis; 2005
40. Robinson MJ, Levenson JL. The use of psychotropics in the medically ill. Curr Psychiatry Rep 2000; 2: 247-55
41. Kawai N, Yamakawa Y, Baba A, et al. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose reduction. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1009-14
42. Chadwick B, Waller DG, Edwards JG. Potential hazardous drug interactions with psychotropics. Adv Psychiatr Treat 2005; 11: 440-9
43. Trenton A, Currier GW, Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 2003; 17: 307-24
44. van de Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 2005; 27: 478-83
45. Mulder H, Herder A, Wilmink FW, et al. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf 2006; 15: 107-14
46. Meltzer HY. Treatment-resistant schizophrenia: the role of clozapine. Curr Med Res Opin 1997; 14: 1-20
47. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second generation antipsychotics in patients with treatment resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-26
48. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-10
49. Lerner V, Bergman J, Borokov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005; 28: 66-71
50. Zink M, Knopf U, Henn FA, et al. Combination of clozapine and amisulpride in treatment resistant schizophrenia: case reports and review of the literature. Pharmacopsychiatry 2004; 37: 26-31
51. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004; 110: 292-8
52. Lim S, Pralea S, Schnitt J, et al. Possible increased efficacy of low-dose clozapine when combined with aripiprazole [letter]. J Clin Psychiatry 2004; 65: 1284
53. Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment resistant schizophrenia: a clinical observation. Clin Drug Invest 2006; 26: 117-24
54. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double blind, placebo-controlled trial. Am J Psychiatry 2005; 162: 130-6
55. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472-82
56. Stahl SM. Antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int J Neuropsychopharmacol 2004; 7: 113-6
57. Tapp AM, Wood AE, Kilzieh N, et al. Antipsychotic polypharmacy: do the benefits justify the risks? [letter] Ann Pharmacother 2005; 39: 1759-60
58. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161: 700-6
59. Centorrino F, Fogarty KV, Sani G, et al. Use of combinations of antipsychotics: McLean Hospital inpatients 2002. Hum Psychopharmacol 2005; 20: 485-92
60. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325-9
61. Fleming J, Chetty M. Psychotropic drug interactions with valproate. Clin Neuropharmacol 2005; 28: 96-101
62. Spina E, Pisani F, Perucca F. Clinically significant drug interactions with carbamazepine. Clin Pharmacokinet 1996; 31: 198-214
63. LaPointe NMA, Curtis LH, Chan KA, et al. Frequency of high risk use of QT prolonging medications. Pharmacoepidemiol Drug Saf 2006; 15: 361-8
64. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003; 114: 135-41
65. Lambert T, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003; 178: S67-70
66. Drug interactions: cytochrome P450 system. Defining genetic influences on pharmacologic responses [online]. Available from URL: http://medicine.iupui. edu/flockhart/ [Accessed 2006 Sep 27]
67. de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004; 55: 491-3
68. Dereme DL, Baldessarini RJ. Clozapine toxicity associated with smoking cessation. Am J Ther 2005; 12: 469-71
69. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia. Technology appraisal TA042. London: National Institute for Health and Clinical Excellence, 2002. Available from URL: http://www.nice.org.uk/page.aspx?.o = ta043 [Accessed 2006 Sep 27]
70. Taylor D, Young C, Esop R, et al. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004; 185: 152-6
71. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005; 25: 32-41
72. Hazell L, Shakir SAW. Under reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385-96
73. van Grootheest K, van Puijenbroek EP, de Jong-van den Berg LTW. Do pharmacists' reports of adverse drug reactions reflect patients' concerns? Pharm World Sci 2004; 26: 155-9